• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

AJMC® in the Press, May 17, 2019


Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

An article from Medical Tourism Magazine included a study from The American Journal of Managed Care® (AJMC®) on medication nonadherence. The study, “Using Aggregated Pharmacy Claims to Identify Primary Nonadherence,” found that medication fill data within the provider electronic health record can identify primary nonadherence in clinical practice. According to the researchers, as adoption of the technology increases, it will offer an opportunity to intervene to improve adherence to therapy.

The National Pharmaceutical Council’s Monday CER Daily Newsfeed included an article from AJMC®’s sister site The Center for Biosimilars®. The article, “HTA Frameworks for RA Therapies Need Improvement, Researchers Say,” covered a paper that said current health technology assessments for rheumatoid arthritis rely on disease activity measures that are not aligned to guideline-recommended target measures of remission and that they might even be biased in favor of certain therapies insofar as they privilege measures like C-reactive protein reduction.

Regulatory Affairs Professionals Society’s Regulatory Focus mentioned The Center for Biosimilars®’ article “Abbvie and Boehringer Ingelheim Settle Over Biosimilar Adalimumab,” which covered AbbVie’s announcements that it had settled its patent litigation with Behringer Ingelheim (BI) over adalimumab. Under the terms of the settlement, BI’s biosimilar, Cyltezo, will not enter the market until July 1, 2023.

The Biologics Prescribers Collaborative’s Biologics & Biosimilars Update highlighted an article from The Center for Biosimilars® on the FDA’s approval of Samsung Bioepis’ etanercept biosimilar, SB4, as Eticovo. According to article, “FDA Approves Samsung Bioepis’ Etanercept Biosimilar, Eticovo,” the biosimilar was approved to treat all indications of its reference, Enbrel: rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.

Related Videos
James Robinson, PhD, MPH, University of California, Berkeley
Video 1 - "NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer"
Patrick Vermersch, MD, PhD
Camilla Levister
dr daniel ontaneda
James Robinson, PhD, MPH, University of California, Berkeley
Shauna Downs, PhD, MS | Image Credit: Rutgers School of Public Health
Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic
Related Content
© 2024 MJH Life Sciences
All rights reserved.